( Figure 1B) . The in vitro-methylated GST-TAF10 (120-
This indicates that SET9 can monomethylate TAF10, similar to histone 3.
To test whether endogenous TAF10 is methylated, 206) protein was subjected to partial trypsin digestion, followed by HPLC purification and Edman degradation nuclear extracts from HeLa cells were immunoprecipitated with two different TAF10 antibodies followed by of the resulting peptides. This analysis revealed lysine 189 as the site of modification (data not shown). This Western blot analysis using a pan-methyl-lysine antibody. As judged by the characteristic double band sigwas further confirmed by in vitro MTase assays using mutated full-length recombinant TAF10 proteins as subnal (Jacq et al., 1994) , this antibody efficiently reacted with the immunoprecipitated TAF10 (Figure 2A ). Furtherstrates. SET9 was able to methylate all lysine mutants except TAF10-K189Q ( Figure 1B) . When a synthetic pepmore, a similar 30 kDa signal could also be observed in TBP immunoprecipitates, suggesting that TAF10 is tide spanning the 180-195 amino acid region of TAF10 was used as a substrate, we observed that SET9 could methylated within the TFIID complex. The in vivo methylation of TAF10 was further substantiated by in-nucleo methylate the unmodified peptide but not peptides that metabolic labeling experiments. HeLa cell nuclei were type human TAF10 or TAF10K189Q expressed comparable levels of the transgenes in a doxycycline-dependent incubated with 3 H-SAM, and after salt extraction, the soluble proteins were immunoprecipitated with a TAF10 manner ( Figure 3B ). Importantly, TAF10 methylation could only be observed in wt TAF10-expressing cells, antibody. A 30 kDa double band corresponding to TAF10 could be detected by autoradiography ( Figure 2B) . further corroborating the notion that TAF10 methylation occurs at lysine 189. The anti-TAF10 antibody coimmuTo address the question whether SET9 is involved in the in vivo methylation of TAF10, we first examined the noprecipitated several TFIID subunits from both wt TAF10 and TAF10K189Q cells ( Figure 3B) , showing that interaction of the endogenous proteins. As shown in Figure 2C , an antibody against SET9 specifically immuboth proteins can integrate into endogenous TFIID complexes. The efficient rescue of the TAF10 Ϫ/Ϫ lethal phenoprecipitated endogenous TAF10 together with other components of the TFIID complex (TBP, TAF6, and notype by the K189Q mutant suggested that TAF10 methylation may not play a major role in the transcription TAF7), pointing to the in vivo association of SET9 with TFIID. Next, HA-tagged wild-type and K189Q mutant of the cell cycle-regulated genes, the downregulation of which has been attributed to the G 0 /G 1 arrest and TAF10 proteins were overexpressed in cells alone or together with SET9, followed by nuclear extract preparaapoptosis of cells lacking TAF10 (Metzger et al., 1999 Figure 2D ). As excgi/content/full/14/2/175/DC1). The expression of individual genes was examined by RT-PCR of RNAs prepected, only the wild-type but not the K189Q mutant TAF10 exhibited immunoreactivity with the pan-methylpared from the two cell lines before and after induction by retinoic acid ϩ cAMP. The expression of two TAF10-lysine antibody, albeit both proteins interacted with SET9 ( Figure 2D ). Thus, TAF10K189Q is not methylated dependent genes (A. Soldatov and L.T., unpublished data), ERF1 and the RA-inducible ERA1 gene, was compromised in vivo at another position. Importantly, SET9 overexpression significantly increased the pan-methyl-lysine (about 2-fold reduction) in the TAF10K189Q-expressing cell line, both before and after parietal endoderm differantibody-reactive signal in the immunoprecipitates containing wild-type TAF10 ( Figure 2D ). These results dementiation ( Figure 3D ). In contrast, the expression of other genes, such as HPRT and cyclin E, was not affected, onstrate that SET9 can methylate TAF10 in vivo and that methylation does not affect TAF10 incorporation suggesting that the effect of TAF10 methylation on transcription is gene specific. into TFIID.
The functional role of TAF10 methylation in gene actiTo test whether this difference is due to the selective recruitment of SET9 to the different regulatory regions, vation was investigated by complementation of TAF10 null mouse F9 cells by the TAF10K189Q mutant. Condiwe performed chromatin immunoprecipitation (ChIP) assays using wild-type F9 cells induced by retinoic tional disruption of TAF10 in F9 cells was performed using the Cre-lox strategy as previously described acid ϩ cAMP. As shown in Figure 3E , in SET9 immunoprecipitates significant amounts of DNA corresponding (Metzger et al., 1999) . Inactivation of both alleles has been shown to impair cell viability, which can be rescued to ERA and ERF1 promoters could be detected, while the signal obtained for cyclin E and HPRT promoter by conditional ectopic expression of wild-type human TAF10 (Metzger et al., 1999) . Cells containing one knock-DNA was hardly above background levels. Since TAF10 occupancy and H3-K4 methylation could be detected out and one floxed allele of TAF10 (L Ϫ /L2) and the reverse tetracycline-controlled rtTA expression vector in all four genes ( Figure 3E ), these data suggest that the gene-specific effect of TAF10 methylation is mediated were stably transfected with vectors containing the TAF10K189Q cDNA or yeast TAF10 cDNA under the by differential recruitment of SET9 to the specific gene regulatory regions. Comparing the ChIP signals obcontrol of the tetracycline operator. Doxycycline-inducible expression of the transgene was verified by Western tained for the ERA and ERF-1 genes, we observed an about 2-and 2.5-fold difference between the two genes blot analysis using the human-specific TAF10 antibody 2F4 ( Figure 3A) . These cells were then electroporated in ␣K4-DiMeH3 and ␣TAF10 immunoprecipitates, respectively ( Figure 3E ). Although potential differences in with an expression vector containing the Cre-recombinase and the excision of exon 2, which creates a null the accessibility of the epitopes for the antibodies within the context of the different PICs formed on the two allele (Metzger et al., 1999) , was analyzed by PCR over a period of 11 days. PCR products corresponding to genes can not be excluded, the observed difference may also reflect the different percentage of cells where the excised allele (233 bp) were constantly detected from the first day after Cre treatment throughout the these genes are in an active state at a given time point. As H3-K4 methylation and TAF10 occupancy characterwhole period, suggesting that the proportion of the cells in which the endogenous TAF10 allele has been inactiize active promoters (Kouzarides, 2002; Muller and Tora, 2004 ) and because ERA is expressed at much higher vated is viable when they express TAF10K189Q ( Figure  3C ). As a negative control, we examined the disappearlevels than ERF1 in these cells, we favor the latter explanation. ance of exon 2 in TAF10 (L Ϫ /L2) cells expressing yeast TAF10, which cannot rescue the mouse TAF10 Ϫ/Ϫ cells In order to gain mechanistic insight into the role of TAF10 methylation, we performed "artificial recruitment" (E.S. and L.T., unpublished data). As expected, the 233 bp products could not be detected after 5 days of Cre assays using Gal4-TAF10 fusion constructs. Gal4-TAF10wt, Gal4-TAF10K189Q, and Gal4-TAF10K189R intreatment ( Figure 3C ). TAF10
Ϫ/Ϫ cells rescued by wild- duced transcription of a Gal4-responsive reporter about or the K189Q mutant form of TAF10 increased Gal4-VP16-dependent activation about 2-fold, suggesting 80-fold ( Figure 4A) . Importantly, however, SET9 overexpression further potentiated Gal4-TAF10wt-driven tranthat the concentration of endogenous TAF10 is limiting in the cells ( Figure 4C ). SET9 further increased wtTAF10-scription about 30-fold but not that of Gal4-TAF10K189Q or Gal4-TAF10K189R. No such stimulation could be obstimulated activation about 3-fold, an effect that could not be observed with SET9H297A or in cells overexserved by overexpression of a methylase-deficient point mutant of SET9 (SET9H297A) ( Figure 4A ). When activapressing TAF10K189Q. These results suggest that methylation of TAF10 plays an important role in SET9-meditor-induced transcription was tested, we found, as expected (Nishioka et al., 2002) , that wtSET9 but not ated enhancement of activator-induced transcription. As shown above, methylation of TAF10 does not influ-SET9H297A could enhance Gal4-VP16-mediated activation ( Figure 4B) . A similar effect (about 2.8-fold inducence its incorporation into or the integrity of TFIID complex. Therefore, we sought to investigate other charaction) was observed with the RXR/RAR-responsive reporter but not with the NFkB p65-or HNF-1-responsive teristics of the protein that could be influenced by this modification. As a result of a broader screen, we found reporters, suggesting that SET9 action is promoter specific ( Figure 4B) . Overexpression of either the wild-type that TAF10 is associated with RNA polymerase II in nu- methylation-dependent transcriptional enhancement was observed only in a subset of TAF10-dependent genes, including ERA and ERF1. This specificity may arise from the selective recruitment of SET9 into the individual promoters. Indeed, we demonstrate a specific in vivo recruitment of SET9 to the ERA and ERF1 promoters but not to those of cyclin E or HPRT. In addition, SET9 could potentiate transcription driven by some activators (e.g., Gal4-VP16 or RXR/RAR) but not those driven by others (e.g., NFB or HNF-1).
SET9 has been identified as a site-specific histone methyltransferase that methylates histone 3 at the lysine 4 position. This modification also correlates with gene activation. Although it was documented that H3 assembled into nucleosomes is a poor substrate for SET9, the role of H3 methylation in SET9 action cannot be excluded (Nishioka et al., 2002) . On the other hand, evidence obtained by in vivo TAF10 replacement experiments suggests that TAF10 methylation represents an important part of the mechanism involved in SET9-dependent transcriptional enhancement. Unlike cells expressing high levels of wild-type TAF10, those overexpressing the methylation-deficient mutant of TAF10 were not responsive to SET9 in functional assays. Although the molecular details remain to be determined, it is tempting to speculate that TAF10 and histone H3 modifications may represent interdependent, sequential molecular steps in the mechanism of SET9-regulated transcription. In this respect we note that H3-K4 methylation did not correlate with SET9 occupancy on cyclin E and HPRT promoters, suggesting that, at least in these genes, the particular histone modification is catalyzed by another methylase. In F9 cells expressing the methylation-deficient mutant of TAF10, transcription of specific targets, such as ERF1 or ERA1, was impaired but not erased entirely. This suggests that SET9-induced TAF10 methylation alone plays a "fine tuning," rather than a decisive, role in the transcription of these genes. Such fine-tuning mechanisms can provide the cells with the potential to influence the efficiency of the transcription machinery in subtle ways, thus contributing to the generation of well-controlled intracellular levels of the individual gene products in a given physiological condition.
TAF10 is an integral component of TFIID, which plays an "integrator" role in the assembly of preinitiation complexes on active promoters, via core promoter recogni- immunoprecipitates were analyzed by real-time PCR using SYBR green.
In Vitro Methyltransferase Assays
In vitro methyltransferase assays were performed in a 30 l reaction
